Merck KGaA’s Bavencio And Mavenclad Growth Steal Show During Q2 Earnings
With Double-Digit Growth
Executive Summary
Sky-high sales growth of the German major’s Bavencio and Mavenclad caught the eye of some observers as the firm continues to advance these drugs in new disease settings to unlock their full potential.